Amneal制药 AMRX 深 沪
等待开盘 05-14 09:30:00 美东时间
12.39
-0.210
-1.67%
华盛通- 最 高12.645
- 今 开12.52
- 成交量 145.83万股
- 最 低 12.34
- 昨 收 12.60
- 总市值 39.52亿
- 52周最高 15.42
- 市盈率 静 55.86
- 换手率 0.46%
- 52周最低 7.07
- 委 比 75.24%
- 总股本 3.19亿
- 历史最高 24.48
- 量 比 0.94
- 振 幅 2.42%
- 历史最低 1.24
- 每 手 1
- 风险率 2.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amneal Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY26 outlook
Amneal Pharmaceuticals press release (AMRX): Q1 Non-GAAP EPS of $0.27 beats by $0.10. Revenue of $722.52M (+3.9% Y/Y) beats by $5.74M. Adjusted EBITDA in the first quarter of 2026 was $202 million, an...
05-08 12:51
Earnings Scheduled For May 1, 2026
Companies Reporting Before The Bell • WisdomTree (NYSE:WT) is projected to repo...
05-01 19:11
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
04-22 19:15
Amneal to Acquire Kashiv, Expanding Biosimilars Platform
Amneal Pharmaceuticals ( ($AMRX) ) just unveiled an announcement. On April 21, ...
04-22 18:53
BRIEF-Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million Vs. IBES Estimate USD 3,097 Million
BRIEF-Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million Vs. IBES Estimate USD 3,097 Million Apr 22 (Reuters) - Amneal Pharmaceuticals outlook FY capex USD 110 million. outlook FY adjusted EBITDA USD 740-770 million outlook FY operating cash flow USD 350-400 million
04-22 18:00
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19
UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.
04-17 21:15
FDA Takes Step Forward on Testosterone Therapy for Men
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
04-16 23:37
Amneal to Report First Quarter 2026 Results on May 1, 2026
Amneal Pharmaceuticals announced it will release its Q1 2026 financial results on May 1, 2026, before market open. The company will host an audio webcast at 8:30 a.m. ET, accessible via its Investor Relations website or by dialing 1 (833) 461-5787 with access code 458312872. A replay will be available post-call. Amneal, a global biopharmaceutical leader, focuses on affordable and innovative medicines, with a portfolio of over 300 products and 160...
04-07 20:01
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
Amneal Pharmaceuticals donated $2 million to support Parkinson’s disease patients during Parkinson’s Awareness Month, reflecting its commitment to expanding access to essential medicines. The company has donated $3.5 million over two years to help eligible patients manage costs for FDA-approved Parkinson’s medications and improve access to education and support. Amneal also emphasizes raising awareness and fostering connections within the Parkins...
04-07 12:00
